Corrigendum: Interpretation guidance for MHRA regulatory considerations for phage therapeutic products (Microbiology 2025;171, doi: 10.1099/mic.0.001613)

Carmen Coxon; Elizabeth Bell; Evelien Adriaenssens; Jason Clark; Joe Edwards; Tas Gohir; Francesca Hodges; Josh Jones; Cath Rees; Annette Sansom; Darren Smith; Mark Sutton; Clare Trippett; Dann Turner

doi:10.1099/mic.0.001670

Corrigendum: Interpretation guidance for MHRA regulatory considerations for phage therapeutic products (Microbiology 2025;171, doi: 10.1099/mic.0.001613)

Carmen Coxon^*, Elizabeth Bell, Evelien Adriaenssens, Jason Clark, Joe Edwards, Tas Gohir, Francesca Hodges, Josh Jones, Cath Rees, Annette Sansom, Darren Smith, Mark Sutton, Clare Trippett, Dann Turner

^*Corresponding author for this work

School of Geography and Natural Sciences

Research output: Contribution to journal › Comment/debate

Abstract

The authors wish to add the following disclaimer to their article: ‘This document reflects the views of subject matter experts from the Innovate UK Phage Innovation Network and the MHRA Science Campus and should not be construed to represent the official view of any given regulatory authority.’ In line with this request, the version of record will also be updated to include the disclaimer text.

Original language	English
Article number	001670
Number of pages	1
Journal	Microbiology
Volume	172
Issue number	2
DOIs	https://doi.org/10.1099/mic.0.001670
Publication status	Published - 24 Feb 2026

Access to Document

10.1099/mic.0.001670Licence: CC BY

mic001670Final published version, 134 KBLicence: CC BY

Cite this

Coxon, C., Bell, E., Adriaenssens, E., Clark, J., Edwards, J., Gohir, T., Hodges, F., Jones, J., Rees, C., Sansom, A., Smith, D., Sutton, M., Trippett, C., & Turner, D. (2026). Corrigendum: Interpretation guidance for MHRA regulatory considerations for phage therapeutic products (Microbiology 2025;171, doi: 10.1099/mic.0.001613). Microbiology, 172(2), Article 001670. https://doi.org/10.1099/mic.0.001670

@article{88b610dd88204227b9a4437585b2afcb,

title = "Corrigendum: Interpretation guidance for MHRA regulatory considerations for phage therapeutic products (Microbiology 2025;171, doi: 10.1099/mic.0.001613)",

abstract = "The authors wish to add the following disclaimer to their article: {\textquoteleft}This document reflects the views of subject matter experts from the Innovate UK Phage Innovation Network and the MHRA Science Campus and should not be construed to represent the official view of any given regulatory authority.{\textquoteright} In line with this request, the version of record will also be updated to include the disclaimer text.",

author = "Carmen Coxon and Elizabeth Bell and Evelien Adriaenssens and Jason Clark and Joe Edwards and Tas Gohir and Francesca Hodges and Josh Jones and Cath Rees and Annette Sansom and Darren Smith and Mark Sutton and Clare Trippett and Dann Turner",

year = "2026",

month = feb,

day = "24",

doi = "10.1099/mic.0.001670",

language = "English",

volume = "172",

journal = "Microbiology",

issn = "1350-0872",

publisher = "Microbiology Society",

number = "2",

}

Coxon, C, Bell, E, Adriaenssens, E, Clark, J, Edwards, J, Gohir, T, Hodges, F, Jones, J, Rees, C, Sansom, A, Smith, D, Sutton, M, Trippett, C & Turner, D 2026, 'Corrigendum: Interpretation guidance for MHRA regulatory considerations for phage therapeutic products (Microbiology 2025;171, doi: 10.1099/mic.0.001613)', Microbiology, vol. 172, no. 2, 001670. https://doi.org/10.1099/mic.0.001670

TY - JOUR

T1 - Corrigendum

T2 - Interpretation guidance for MHRA regulatory considerations for phage therapeutic products (Microbiology 2025;171, doi: 10.1099/mic.0.001613)

AU - Coxon, Carmen

AU - Bell, Elizabeth

AU - Adriaenssens, Evelien

AU - Clark, Jason

AU - Edwards, Joe

AU - Gohir, Tas

AU - Hodges, Francesca

AU - Jones, Josh

AU - Rees, Cath

AU - Sansom, Annette

AU - Smith, Darren

AU - Sutton, Mark

AU - Trippett, Clare

AU - Turner, Dann

PY - 2026/2/24

Y1 - 2026/2/24

N2 - The authors wish to add the following disclaimer to their article: ‘This document reflects the views of subject matter experts from the Innovate UK Phage Innovation Network and the MHRA Science Campus and should not be construed to represent the official view of any given regulatory authority.’ In line with this request, the version of record will also be updated to include the disclaimer text.

AB - The authors wish to add the following disclaimer to their article: ‘This document reflects the views of subject matter experts from the Innovate UK Phage Innovation Network and the MHRA Science Campus and should not be construed to represent the official view of any given regulatory authority.’ In line with this request, the version of record will also be updated to include the disclaimer text.

UR - https://www.scopus.com/pages/publications/105031190694

U2 - 10.1099/mic.0.001670

DO - 10.1099/mic.0.001670

M3 - Comment/debate

C2 - 41734086

AN - SCOPUS:105031190694

SN - 1350-0872

VL - 172

JO - Microbiology

JF - Microbiology

IS - 2

M1 - 001670

ER -

Corrigendum: Interpretation guidance for MHRA regulatory considerations for phage therapeutic products (Microbiology 2025;171, doi: 10.1099/mic.0.001613)

Abstract

Access to Document

Other files and links

Fingerprint

Interpretation guidance for MHRA regulatory considerations for phage therapeutic products

Cite this